Dipartimento di Medicina interna e terapia medica

Contenuti del sito

Menu di navigazione - Torna all'inizio


Contenuto della pagina - Torna all'inizio


Alberto Riccardi

Professore Ordinario
Sede:
Unità di Endocrinologia e Oncologia Medica c/o Fondazione Maugeri Pavia
Telefono+ 39 0382 592651
Fax+ 39 0382 592078
E-mailalberto.riccardi@unipv.it
Curriculumcurriculum Riccardi
Pubblicazioni1) Riccardi, A, Mora, O., Brugnatelli, S., Ucci, G., Spanedda, R., De Paoli, A., Barbarano, L., Di Stasi, M, Giordano, M., Delfini, C., Nicoletti, G., Morandi, S., Rinaldi, E., Piccinini, L., Ascari, E. (for the Cooperative Group of Study and Treatment of Multiple Myeloma) - Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: results of the MM87 prospective randomised protocol. Br J Cancer 77; 485-491, 1998.
2) Riccardi, A., Tinelli, C., Pugliese, P., Brugnatelli, S., Giordano, M., Danova, M., Richetti, A., Fava, S., Nastasi, P., Rinaldi, E., Fregoni, V., De Monte, A., Trotti, G. (for the Cooperative Group of Study and Treatment of Breast Cancer) - Doubling the epirubicin dosage in the 5-fluorouracil, epirubicin and cyclophosphamide (FEC) regimen for advanced breast cancer: a prospective, randomized, multicentric study on antitumor effect and life quality. Int J Oncol 16; 769-76, 2000.
3) Riccardi, A., Pugliese, P., Danova, M., Brugnatelli, S., Grasso, D., Giordano, M., Bernardo, G., Giardina, G., Fava, S., Montanari, G., Pedrotti, C., Poli, M.A., Tinelli, C. – A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer. Br J Cancer 85; 141-146, 2001.
4) Riccardi, A., Mora, O., Tinelli, C., Porta, C., Danova, M,. Brugnatelli, S., Grasso, D., Tolcà, B., Spanedda, R., De Paoli, A., Barbarano, L., Cavanna, L, Giordano, M., Delfini, C., Nicoletti, G., Bergonzi, C., Rinaldi, E., Piccinini, L., Ascari, E. (for the Cooperative Group of Study and Treatment of Multiple Myeloma) - Response to first line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Europ J Cancer 39; 31-37, 2003.
5) Della Porta, M., Danova, M., Rigolin, G.M., Brugnatelli, S., Rovati, B., Tronconi, C., Fraulini, C., Russo Rossi, A., Riccardi, A., Castoldi, G.L. - Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 68: 276-284, 2005.
6) Paccagnella, A., Oniga, F., Bearz, A., Favaretto, A., Clerici, M., Barbieri, F., Riccardi, A., Chella, A., Tirelli, U., Ceresoli, G., Tumolo, S., Ridolfi, R., Biason, R., Nicoletto, M.O., Belloni, P., Veglia, F., Ghi, M.G.. - Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non small cell lung cancer: results of a phase III study. J Clin Oncol 24; 681 – 687, 2006.
7) Invernizzi R, Grasso D, Travaglino E, Benatti C, Collovà E, Manzoni M, Danova M, Riccardi A. - Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose - dense chemotherapy. Oncology 75; 237 – 244, 2008.
8) Zambelli, A., Della Porta, MG., Eleuteri,E., Degiuli, L., Catalano, O., Tondini. C., Riccardi, A. - Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast 20; 176 - 83, 2011.
9) Fregoni V, Regolo L, Da Prada GA, Zambelli A, Baiardi P, Zanini V, Villani L, Pavesi L, Riccardi A.- No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer. Breast. Breast 21; 220 -1, 2012
10) Poggi, G., Montagna, B., Di Cesare, P., Riva, G., Bernardo, G., Mazzucco, M., Riccardi, A. - Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. .Anticancer Res 33, 1221-7, 2013.